BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• MiMedx Adds New Materials to its Website Exposing Misinformation Disseminated Through Short Sellers

  MiMedx announced today that it has posted additional materials on the Company’s website that further expose the misinformation disseminated through short sellers.

  November 14, 2017

   · 

  3 min read
• BioMidwest

  Esperion to Participate in Fireside Chat at the Jefferies 2017 London Healthcare Conference

  Esperion today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat with investors at the Jefferies 2017 London Healthcare Conference in London on Thursday, November 16, 2017 at 1:20 p.m. Greenwich Mean Time / 8:20 a.m. Eastern Time.

  November 14, 2017

   · 

  3 min read
• MagForce AG to Participate at SNO 2017 Annual Meeting From November 16-19 in San Francisco, USA

  MagForce AG today announced its participation in the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, SNO 2017, held from November 16-19, 2017, in San Francisco, California, USA.

  November 14, 2017

   · 

  5 min read
• BerGenBio to Present BGB324 and KEYTRUDA (pembrolizumab) Clinical Trial at the 2017 San Antonio Breast Cancer Symposium

  The poster presentation will describe the rationale and design of the combination study with KEYTRUDA and BGB324, a first-in-class and highly selective small molecule Axl kinase inhibitor, which is being developed to target tumour immune evasion and resistance.

  November 14, 2017

   · 

  1 min read
• ProQR Announces Proposed Public Offering of Ordinary Shares

  ProQR expects to grant the underwriters a 30-day option to purchase additional ordinary shares, on the same terms and conditions.

  November 14, 2017

   · 

  3 min read
• Drug Development

  Amarin: Vascepa (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Patients With Persistent High Triglycerides and Chronic Kidney Disease

  This oral presentation was held at the American Heart Association (AHA) 2017 Scientific Sessions in Anaheim, California.

  November 14, 2017

   · 

  8 min read
• Business

  Acura Pharmaceuticals Announces Third Quarter 2017 Financial Results

  The Company reported a net loss of $2.2 million or $0.12 per diluted share for quarter ended September 30, 2017 compared to a net loss of $2.3 million or $0.19 per diluted share for the same period in 2016.

  November 14, 2017

   · 

  8 min read
• Specialty Diagnostic Company IQuity Introduces First RNA-Based Blood Test to Identify IBS and IBD

  IsolateIBS-IBD uses a simple blood draw to identify, with greater than 90 percent accuracy, if a patient’s RNA profile indicates the presence of IBS or IBD.

  November 14, 2017

   · 

  2 min read
• Business

  Cloud Technology Veteran, Lili Nader, Named CTO of Riffyn

  Ms. Nader is a co-founder of Riffyn and served as the chief software architect of Riffyn’s cloud-based SDE since 2014.

  November 14, 2017

   · 

  2 min read
• Drug Development

  Akcea Initiates AKCEA-ANGPTL3-LRx Phase II Program in Patients With Rare Hyperlipidemias

  AKCEA-ANGPTL3-LRx is designed to reduce the production of angiopoietin-like 3, or ANGPTL3.

  November 14, 2017

   · 

  8 min read